IL319505A - ווסתי רצפטור s1p 1 לשימוש בטיפול במחלות המתווכות ע" י אינטרפרון מסוג 1 - Google Patents

ווסתי רצפטור s1p 1 לשימוש בטיפול במחלות המתווכות ע" י אינטרפרון מסוג 1

Info

Publication number
IL319505A
IL319505A IL319505A IL31950525A IL319505A IL 319505 A IL319505 A IL 319505A IL 319505 A IL319505 A IL 319505A IL 31950525 A IL31950525 A IL 31950525A IL 319505 A IL319505 A IL 319505A
Authority
IL
Israel
Prior art keywords
treatment
type
receptor modulators
mediated diseases
ifn mediated
Prior art date
Application number
IL319505A
Other languages
English (en)
Inventor
Daniel Strasser
Mark Murphy
Original Assignee
Viatris Asia Pacific Pte Ltd
Daniel Strasser
Mark Murphy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Asia Pacific Pte Ltd, Daniel Strasser, Mark Murphy filed Critical Viatris Asia Pacific Pte Ltd
Publication of IL319505A publication Critical patent/IL319505A/he

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245Oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL319505A 2022-09-14 2023-09-12 ווסתי רצפטור s1p 1 לשימוש בטיפול במחלות המתווכות ע" י אינטרפרון מסוג 1 IL319505A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263375668P 2022-09-14 2022-09-14
PCT/EP2023/074961 WO2024056631A1 (en) 2022-09-14 2023-09-12 S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases

Publications (1)

Publication Number Publication Date
IL319505A true IL319505A (he) 2025-05-01

Family

ID=88093165

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319505A IL319505A (he) 2022-09-14 2023-09-12 ווסתי רצפטור s1p 1 לשימוש בטיפול במחלות המתווכות ע" י אינטרפרון מסוג 1

Country Status (11)

Country Link
EP (1) EP4587005A1 (he)
JP (1) JP2025531208A (he)
KR (1) KR20250065853A (he)
CN (1) CN119866215A (he)
AU (1) AU2023339761A1 (he)
CA (1) CA3266513A1 (he)
CL (1) CL2025000741A1 (he)
IL (1) IL319505A (he)
MX (1) MX2025003112A (he)
TW (1) TW202416967A (he)
WO (1) WO2024056631A1 (he)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2767585C (en) 2009-07-16 2017-09-26 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives
CA2772921A1 (en) 2009-09-03 2011-03-10 Medimmune, Llc Type 1 interferon diagnostic
EP2852575A1 (en) 2012-05-22 2015-04-01 Actelion Pharmaceuticals Ltd. New process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid
PH12017502097B1 (en) 2015-05-20 2023-05-05 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
JP2022512796A (ja) 2018-10-26 2022-02-07 ヤンセン バイオテツク,インコーポレーテツド I型インターフェロンシグネチャー及び使用方法
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療

Also Published As

Publication number Publication date
MX2025003112A (es) 2025-05-02
CA3266513A1 (en) 2024-03-21
JP2025531208A (ja) 2025-09-19
CN119866215A (zh) 2025-04-22
CL2025000741A1 (es) 2025-05-23
WO2024056631A1 (en) 2024-03-21
AU2023339761A1 (en) 2025-03-20
TW202416967A (zh) 2024-05-01
KR20250065853A (ko) 2025-05-13
EP4587005A1 (en) 2025-07-23

Similar Documents

Publication Publication Date Title
EP3755805A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT OF NON-AGE-RELATED HEARING DAMAGE IN AN INDIVIDUAL
IL285647A (he) חומר ומערכת לטיפול התרפויטי במפרקים
EP3934646A4 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EYE DISEASES OR CONDITIONS
SG11202007082PA (en) Composition used for therapeutic treatment of skin disease
EP3362096A4 (en) OPHTHALMIC TREATMENT COMPOSITION AND CARRIER FOR THE RELEASE OF PHARMACEUTICAL SUBSTANCES OR THERAPEUTICS
CY1125113T1 (el) Συνθεσεις και μεθοδοι για χρηση στην αγωγη της ομοκυστινουριας
EP3960858A4 (en) SMALL RNA DRUG USED TO PREVENT AND TREAT INFLAMMATION-RELATED DISEASES AND COMBINATIONS THEREOF
EP3856168A4 (en) COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISEASES
EP4058017A4 (en) DRUG FORMULATIONS AND METHODS OF TREATMENT OF METABOLIC DISORDERS
EP3479826A4 (en) USE OF METHYL-4- [9- (6-AMINOPURYL)] - 2 (S) -HYDROXYBUTYRATE FOR THE PRODUCTION OF A MEDICINE FOR THE TREATMENT OF PSORIASIS AND VITILIGO
ZA202101688B (en) Pharmaceutical compositions suitable for articular delivery and use thereof in treatment of joint pain
PT4031117T (pt) Mutante do ngf para utilização no tratamento ou prevenção de distúrbios oftálmicos
IL319505A (he) ווסתי רצפטור s1p 1 לשימוש בטיפול במחלות המתווכות ע" י אינטרפרון מסוג 1
PH12020550722A1 (en) Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye
EP4232819A4 (en) METHODS FOR EVALUATING THE THERAPEUTIC ACTIVITY OF AGENTS FOR THE TREATMENT OF IMMUNE DISEASES
IL326583A (he) אנלוגים יציבים של glp-1 לטיפול במחלות והפרעות אנושיות
SMT202500307T1 (it) Derivati di 1-metil-1h-pirazol-3-ile per l’uso nel trattamento di malattie neovascolari
EP3549596A4 (en) USE OF MICROCYSTINES FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE PREVENTION OR TREATMENT OF ORGANIC AND TISSUE FIBROSE DISEASES
PT3937948T (pt) Fitoecdisonas e seus derivados para utilização no tratamento de doenças neuromusculares
IL277041A (he) מאפנני תעלות אשלגן משופעלי סידן עם מוליכות קטנה ותכשירי רוקחות לשימוש בטיפול בהפרעות פרוזדוריות מפגיעה
EP3386516A4 (en) PHARMACEUTICAL FORMULATIONS FOR TREATING SKIN DISEASES AND METHOD FOR THE PRODUCTION AND USE THEREOF
LT4048229T (lt) Farmacinė kompozicija, skirta panaudoti įvairių etiologijų cistito gydymui
IL304606A (he) שילובים רפואיים של רוסובסטטין ורזמטירום לטיפול בהפרעות כבד או הפרעות שומנים
CA3261529A1 (en) Hydrogel composition intended for use in the treatment of joint disorders
AU2021381054A9 (en) Pharmaceutical compositions for use in the management and treatment of pain